ADVERTISEMENT
ADVERTISEMENT

Autoimmunity

Edited by: Thomas W. Durso D.J. Lenschow, S.C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K.C. Herold, J.A. Bluestone, "Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse," Journal of Experimental Medicine, 181:1145-55, 1995 (Cited in more than 100 papers as of April 1997) Comments by Jeffrey A. Bluestone, Ben May Institute, University of Chicago ONE OR THE OTHER: Jeffrey Bluestone of the University of C

The Scientist Staff

Edited by: Thomas W. Durso
D.J. Lenschow, S.C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K.C. Herold, J.A. Bluestone, "Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse," Journal of Experimental Medicine, 181:1145-55, 1995 (Cited in more than 100 papers as of April 1997)

Comments by Jeffrey A. Bluestone, Ben May Institute, University of Chicago


ONE OR THE OTHER: Jeffrey Bluestone of the University of Chicago helped discover which of two costimulatory molecules is important in the progression of autoimmune diabetes.
While Harvard Medical School's Laurie H. Glimcher was examining the role of the costimulatory molecules B7-1 and B7-2 in experimental allergic encephalomyelitis (EAE), Jeffrey A. Bluestone was studying their role in autoimmune diabetes. B7-1 and B7-2 activate a pair of pathways, Th1 and Th2, along which the immune system's T helper (Th) cells mature. Bluestone,...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT